Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 6.81% | -38.38% | -54.87% | -73.87% | 7.68% |
| Total Depreciation and Amortization | -48.48% | -35.38% | -26.85% | -16.78% | -6.09% |
| Total Amortization of Deferred Charges | 1.97% | -89.91% | -89.55% | -89.94% | -90.29% |
| Total Other Non-Cash Items | 62.18% | 157.28% | 174.34% | 250.08% | -528.81% |
| Change in Net Operating Assets | 656.41% | 32.20% | 246.18% | 191.63% | 90.84% |
| Cash from Operations | 18.17% | 11.87% | 20.04% | 10.85% | -6.33% |
| Capital Expenditure | 95.81% | 96.93% | 97.26% | 78.08% | -11.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -99.59% | -44.69% | 4.21% | -47.32% | 147.89% |
| Cash from Investing | -97.35% | -40.12% | 12.89% | -44.43% | 151.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 97.81% | 98.42% | 97.91% | 89.00% | 76.58% |
| Issuance of Common Stock | 30,106.94% | -66.07% | -66.04% | -66.04% | -99.89% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 86.04% | -102.84% | -102.27% | -- | -117.24% |
| Cash from Financing | 506.33% | -67.17% | -67.01% | -66.83% | -107.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.42% | -166.42% | -163.11% | -138.46% | -205.70% |